ST Germain D J Co. Inc. Grows Holdings in Boston Scientific Co. (NYSE:BSX)

ST Germain D J Co. Inc. boosted its position in Boston Scientific Co. (NYSE:BSX) by 8.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,923 shares of the medical equipment provider’s stock after buying an additional 143 shares during the quarter. ST Germain D J Co. Inc.’s holdings in Boston Scientific were worth $148,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. First Foundation Advisors acquired a new stake in Boston Scientific in the first quarter valued at $25,000. Eagle Bay Advisors LLC raised its stake in shares of Boston Scientific by 542.1% in the 1st quarter. Eagle Bay Advisors LLC now owns 366 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 309 shares in the last quarter. RiverPark Advisors LLC bought a new position in shares of Boston Scientific during the first quarter worth about $30,000. Northwest Investment Counselors LLC acquired a new position in Boston Scientific in the first quarter worth about $31,000. Finally, YHB Investment Advisors Inc. bought a new stake in Boston Scientific in the first quarter valued at about $32,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Price Performance

BSX traded up $0.80 on Tuesday, reaching $73.76. The company had a trading volume of 5,083,571 shares, compared to its average volume of 6,332,000. Boston Scientific Co. has a one year low of $48.35 and a one year high of $79.43. The company has a market capitalization of $108.21 billion, a P/E ratio of 62.38, a PEG ratio of 2.49 and a beta of 0.78. The company has a fifty day moving average of $76.37 and a 200-day moving average of $71.07. The company has a current ratio of 1.66, a quick ratio of 1.14 and a debt-to-equity ratio of 0.47.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.04. Boston Scientific had a net margin of 12.00% and a return on equity of 16.80%. The business had revenue of $4.12 billion during the quarter, compared to analysts’ expectations of $4.02 billion. During the same period last year, the firm posted $0.53 earnings per share. The business’s revenue was up 14.5% on a year-over-year basis. As a group, equities research analysts anticipate that Boston Scientific Co. will post 2.4 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have commented on BSX. Morgan Stanley increased their target price on Boston Scientific from $79.00 to $92.00 and gave the stock an “overweight” rating in a report on Monday, July 15th. Argus raised their price objective on Boston Scientific from $80.00 to $95.00 and gave the stock a “buy” rating in a research note on Tuesday, May 28th. Truist Financial boosted their target price on shares of Boston Scientific from $86.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday, July 16th. Canaccord Genuity Group raised their price target on shares of Boston Scientific from $83.00 to $88.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Finally, Raymond James boosted their price objective on shares of Boston Scientific from $85.00 to $91.00 and gave the company a “strong-buy” rating in a research report on Thursday, July 25th. Two investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $84.76.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 14,011 shares of the company’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $75.34, for a total value of $1,055,588.74. Following the completion of the sale, the executive vice president now directly owns 20,197 shares of the company’s stock, valued at approximately $1,521,641.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, EVP Arthur C. Butcher sold 14,011 shares of Boston Scientific stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $75.34, for a total value of $1,055,588.74. Following the transaction, the executive vice president now directly owns 20,197 shares in the company, valued at approximately $1,521,641.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $74.12, for a total transaction of $517,579.96. Following the sale, the executive vice president now directly owns 40,188 shares of the company’s stock, valued at $2,978,734.56. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 47,891 shares of company stock valued at $3,597,688. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.